Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Almeida, António, Ferreira, Ana Rita, Costa, Maria João, Silva, Sofia, Alnajjar, Khalil, Bogalho, Isabel, Pierdomenico, Francesca, Esteves, Susana, Alpoim, Mafalda, Braz, Gil, Cortesão, Emilia, Pinto, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200877/
https://www.ncbi.nlm.nih.gov/pubmed/28066705
http://dx.doi.org/10.1016/j.lrr.2016.12.002
_version_ 1782489257861971968
author Almeida, António
Ferreira, Ana Rita
Costa, Maria João
Silva, Sofia
Alnajjar, Khalil
Bogalho, Isabel
Pierdomenico, Francesca
Esteves, Susana
Alpoim, Mafalda
Braz, Gil
Cortesão, Emilia
Pinto, Ricardo
author_facet Almeida, António
Ferreira, Ana Rita
Costa, Maria João
Silva, Sofia
Alnajjar, Khalil
Bogalho, Isabel
Pierdomenico, Francesca
Esteves, Susana
Alpoim, Mafalda
Braz, Gil
Cortesão, Emilia
Pinto, Ricardo
author_sort Almeida, António
collection PubMed
description Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.
format Online
Article
Text
id pubmed-5200877
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-52008772017-01-06 Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study Almeida, António Ferreira, Ana Rita Costa, Maria João Silva, Sofia Alnajjar, Khalil Bogalho, Isabel Pierdomenico, Francesca Esteves, Susana Alpoim, Mafalda Braz, Gil Cortesão, Emilia Pinto, Ricardo Leuk Res Rep Article Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment. Elsevier 2016-12-23 /pmc/articles/PMC5200877/ /pubmed/28066705 http://dx.doi.org/10.1016/j.lrr.2016.12.002 Text en © 2017 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Almeida, António
Ferreira, Ana Rita
Costa, Maria João
Silva, Sofia
Alnajjar, Khalil
Bogalho, Isabel
Pierdomenico, Francesca
Esteves, Susana
Alpoim, Mafalda
Braz, Gil
Cortesão, Emilia
Pinto, Ricardo
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title_full Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title_fullStr Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title_full_unstemmed Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title_short Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study
title_sort clinical outcomes of aml patients treated with azacitidine in portugal: a retrospective multicenter study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200877/
https://www.ncbi.nlm.nih.gov/pubmed/28066705
http://dx.doi.org/10.1016/j.lrr.2016.12.002
work_keys_str_mv AT almeidaantonio clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT ferreiraanarita clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT costamariajoao clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT silvasofia clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT alnajjarkhalil clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT bogalhoisabel clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT pierdomenicofrancesca clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT estevessusana clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT alpoimmafalda clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT brazgil clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT cortesaoemilia clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy
AT pintoricardo clinicaloutcomesofamlpatientstreatedwithazacitidineinportugalaretrospectivemulticenterstudy

Ejemplares similares